Bicara Therapeutics Inc. (BCAX) vs Replimune Group, Inc. (REPL)

Bicara Therapeutics Inc. and Replimune Group, Inc. are both Biotechnology companies. Bicara Therapeutics Inc. is the larger, with a market value of $1.3B against $1.2B — 1.1× the size. Across the 10 metrics below, Bicara Therapeutics Inc. leads on 9 and Replimune Group, Inc. on 1.

Valuation

Metric BCAX REPL Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 2.78 11.37 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield (16.14%) (25.40%) (28.84%)
Free cash flow yield (10.36%) (23.36%) (23.03%)

Profitability

Metric BCAX REPL Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (41.01%) (134.29%) (57.72%)
Return on assets (38.38%) (82.28%) (49.22%)
Return on invested capital 0.00% (1,154.69%) 0.00%

Growth

Metric BCAX REPL Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 37.78% (10.10%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BCAX REPL Biotechnology median
Debt to equity 0.00 1.00 0.00
Current ratio 11.59 5.23 4.73
Net debt to EBITDA 2.67 0.51 0.96

Dividend

Metric BCAX REPL Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric BCAX REPL Biotechnology median
Market cap 1.32b 1.20b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack